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Abstract
Background: The peroxisome proliferator-activated receptor α  (PPARα ) plays an important role
in the metabolism of lipoproteins and fatty acids, and seems to protect against the development of
atherosclerosis. To evaluate the possible protective role of PPARα  on cardiovascular function, the
effect of the PPARα  agonist, fenofibrate was assessed with respect to ischaemia/reperfusion injury
and endothelial function in mice.
Results: Fenofibrate treatment reduces myocardial infarction size and improves post-ischaemic
contractile dysfunction. Hearts from PPARα  null mice exhibit increased susceptibility to ischaemic
damages and were refractory to protection by fenofibrate treatment suggesting that the beneficial
effects of fenofibrate were mediated via PPARα . Furthermore, fenofibrate improves endothelium-
and nitric oxide-mediated vasodilatation in aorta and mesenteric vascular bed. A decreased
inhibitory effect of reactive oxygen species in the vessel wall accounts for enhanced endothelial
vasodilatation. However, the latter cannot be explained by an increase in nitric oxide synthase
expression nor by an increase sensitivity of the arteries to nitric oxide.
Conclusions: Altogether the present data suggest that fenofibrate exerts cardioprotective effect
against ischaemia and improves nitric oxide-mediated response probably by enhancing antioxidant
capacity of the vessel wall. These data underscore new therapeutic perspectives for PPARα
agonists in ischaemic myocardial injury and in cardiovascular diseases associated with endothelial
dysfunction.
Background
The peroxisome proliferator-activated receptor α  (PPARα )
is a member of the nuclear hormone receptor superfamily.
PPARα  is activated by several fatty acids and is also the
molecular target of hypolipidemic fibrates. PPARα  plays
an important role in the liver, where it controls the metab-
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olism of lipoproteins and fatty acids [1,2]. In addition,
PPARα  is widely expressed in the entire cardiovascular sys-
tem, including the heart and the different cells that com-
pose the vascular wall, such as endothelial, vascular
smooth muscle, and monocyte/macrophage cells. Activa-
tion of PPARα  increases uptake of fatty acids and activates
their β -oxidation as a result of the induction of many
genes including some coding for lipid binding proteins,
apolipoproteins and those involved in peroxisomal and
mitochondrial fatty acid β -oxidation [2–4]. Fatty acid β -
oxidation seems to play a critical role not only in normal
cardiac metabolic homeostasis but its dysregulation also
contributes to the pathogenesis of a variety of disease
states such as cardiac hypertrophy and heart failure. Re-
cent studies have suggested that PPARα  agonists, in addi-
tion to their beneficial effects on lipid homeostasis, might
reduce the progression of atherosclerotic lesions by a di-
rect anti-atherogenic and anti-inflammatory action [5].
Indeed, PPARα  activation results in the induction of anti-
oxidant enzymes and in the inhibition of the expression
of pro-inflammatory genes, such as interleukin-6, cyclo-
oxygenase 2, and endothelin within vascular cells via neg-
ative regulation of signalling pathways, controlled by the
nuclear factor κ b (NFκ B) and the activator protein-1 (AP-
1). Furthermore, PPARα  inhibits the expression of mono-
cyte-recruiting proteins, such as vascular cell adhesion
molecules [6], induces apoptosis in monocyte-derived
macrophages [7], and reduces tissue factor expression and
activity in monocytes [8,9], accounting for the reduction
of the thrombogenicity of atherosclerotic lesions.
We analyzed here the effect of the PPARα  agonist, fenofi-
brate on the regulation of cardiovascular function with re-
spect to ischaemia-reperfusion myocardial injury and
endothelial dysfunction. Evidence is provided that treat-
ment of mice with fenofibrate via PPARα  reduces myocar-
dial infarction size and improves post-ischaemic
contractile dysfunction, after an ischaemic period. Fur-
thermore, we demonstrate that fenofibrate improves en-
dothelial nitric oxide (NO)-mediated vasodilatation by
increasing the antioxidant defense system of the vessel
wall.
Results
Fenofibrate treatment reduces ischcaemia-induced myo-
cardial infarct
Administration of the PPARα  agonist, fenofibrate, for 10
days to male C57BL/6 mice resulted in a significant de-
crease in body weight as compared to control mice treated
with placebo (Control: 30.1 ± 0.26, n = 21; Fenofibrate:
26.8 ± 0.47, n = 19, P < 0.001). At the end of the treatment
period, hearts from fenofibrate-treated mice weighed sig-
nificantly less than those from control mice (Control:
0.135 ± 0.003 g, n = 9; Fenofibrate: 0.113 ± 0.05 g, n = 8;
P < 0.05). However the heart/body weight ratio was not
altered after fenofibrate treatment (Control: 0.48 ± 0.006
%, n = 9; Fenofibrate: 0.46 ± 0.11%, n = 8).
To analyze the effects of PPARα  activation on myocardial
infarction, hearts were subjected to 30 min global, no-
flow ischaemia at 37°C, followed by 1 h reperfusion. My-
ocardial infarct size was evaluated morphologically using
TTC-staining as an index of irreversible myocardial injury
(Fig. 1A). Fenofibrate treatment significantly reduced is-
chaemia-induced myocardial infarction size by more than
3-fold relative to control mice (P < 0.01) (Fig. 1B).
Fenofibrate improves the post-ischaemic recovery of cardi-
ac function
To determine whether treatment of mice with fenofibrate
protects against ischaemia/reperfusion-induced function-
al injury, ventricular parameters such as developed force,
heart rate, and coronary flow were studied in control and
fenofibrate-treated animals. Basal parameters were not
significantly different between the two groups of mice at
the end of the equilibration period before ischaemia as
(Table 1). After the ischaemic insult, all the hearts from
fenofibrate-treated mice recovered both contractile force
and heart rate whereas only 58% of the hearts in control
mice showed an improvement (Fig. 2A). For the following
Figure 1
Fenofibrate treatment reduces ischaemia-induced myocardial
infarct. (A) Representative images of transversal slices from
ischaemic hearts from control (upper panel) and fenofibrate-
treated (lower panel) mice stained with triphenyltetrazolium
(TTC). The arrows represent unstained areas (white) show-
ing irreversible damaged myocardial tissue. (B) Volume of inf-
arcted myocardium. Data are the mean ± SEM of 6
experiments. **P < 0.01BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/10
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measured parameters, only the values of heart that recov-
ered for the ischaemic insult have been included. Also the
time of recovery of force and heart rate after the ischaemia
was significantly shorter in hearts from fenofibrate-treated
as compared to control mice (Fig. 2B). Recovery of con-
tractile force in hearts from control group was stabilized
after 20 min reperfusion (Fig. 2C). The level of the con-
tractile force recovered was, however, very low (i.e. 13%),
when compared with the contractile force measured be-
fore the induction of the ischaemia. By contrast in hearts
from fenofibrate-treated mice, the recovery in cardiac con-
tractile force was dramatically enhanced (60 % of the ini-
tial force), and did not yet reach maximal values 1 h after
reperfusion. Thus at the end of the reperfusion period, the
developed force was significantly greater in fenofibrate-
treated mice than in control mice. Heart rate recovered
rather quickly and reached a steady state level 30 min after
reperfusion in both groups of mice. The level of heart rate
recovery was, however, significantly higher in fenofibrate-
treated mice when compared to that of control mice (Fig.
2D). The coronary flow rate returned after 20 min of
reperfusion to its initial value before the ischaemic condi-
tion in the two groups of animals and it remained stable
until the end of the reperfusion period (Fig. 2E). Altogeth-
er, these data suggest that fenofibrate treatment markedly
improves myocardial contractile function following is-
chaemia/reperfusion.
Hearts from mice lacking PPARα  (PPARα -/-) were more 
susceptible to post-ischaemic damages and were refracto-
ry to myocardial protection by fenofibrate treatment
To test the role of PPARα , ischaemia/reperfusion-induced
functional injury was conducted in hearts from both PPA-
Rα +/+ and PPARα -/- mice. After the ischaemic insult, the
percentage of hearts recovered from both contractile force
Figure 2
Fenofibrate improves the post-ischaemic recovery of cardiac
function. Percentage of hearts that recover after ischaemic
condition (A), time of recovery (B) and postischaemic recov-
ery of force (C), heart rate (D), and coronary blood flow (E)
in hearts from control and fenofibrate-treated mice. Data are
the mean ± SEM of 7–10 experiments. * P < 0.05, ** P < 0.01.
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Figure 3
Hearts from PPARα -/- mice were more susceptible to post-
ischaemic damages than those from PPARα +/+ mice. Time of
recovery (A) and post-ischaemic recovery of force (B), heart
rate (C), and coronary blood flow (D) in hearts from
PPARα +/+ and PPARα -/- mice. Data are the mean ± SEM of 6
experiments. * P < 0.05, ** P < 0.01.
Table 1: Ventricular functional parameters measured before is-
chaemia in control and fenofibrate-treated mice.
Force (g) Heart rate 
(beats/min)
Coronary 
flow (ml/min)
Control (n = 7) 2.19 ± 0.66 296 ± 42 3.03 ± 1.15
Fenofibrate (n = 10) 3.01 ± 1.09 312 ± 59 3.03 ± 1.29
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and heart rate were not different between PPARα +/+ and
PPARα -/- mice being 75% versus 87% respectively. Howev-
er, the time of recovery of force and heart rate after the is-
chaemia was significantly shorter in hearts from PPARα +/
+ as compared to hearts from PPARα -/- mice (Fig. 3A). Re-
covery of contractile force in hearts from control group
was stabilized after 20 min reperfusion (Fig. 3B). The level
of the contractile force recovered was, however, very low
(i.e. 22%), when compared with the contractile force
measured before the induction of the ischaemia. Interest-
ingly in hearts from PPARα -/- mice, the recovery in cardiac
contractile force was dramatically decreased (8 % of the
initial force), and did not improve 1 h after reperfusion.
Thus at the end of the reperfusion period, the developed
force was significantly lower in hearts from PPARα -/- than
in those from PPARα +/+ mice. Heart rate recovered rather
quickly and reached a steady state level 30 min after reper-
fusion in both groups of mice. The level of heart rate re-
covery was, however, significantly higher in heart from
PPARα +/+ mice when compared to that of PPARα -/- mice
(Fig. 3C). The coronary flow rate returned after 20 min of
reperfusion to its initial value before the ischaemic condi-
tion in PPARα +/+ mice and it remained stable until the
end of the reperfusion period (Fig. 3D). In PPARα -/- mice,
the coronary flow did not returned to its initial values (i.e.
60%). Furthermore, the level of coronary flow recovery in
PPARα -/- mice was significantly lower than the level ob-
tained in heart from PPARα +/+ mice.
Finally, to test whether the protective effect of fenofibrate
treatment against ischaemia/reperfusion-induced func-
tional injury was due to PPARα  activation, experiments
were carried out in heart from mice lacking PPARα  treated
with fenofibrate. Interestingly, no beneficial effect of
fenofibrate on PPARα -/- mice was observed and in fact 5
out of 6 hearts were dead after ischaemia.
Altogether, these data suggest that hearts from PPARα -/-
mice were more susceptible to myocardial dysfunctions
following ischaemia/reperfusion than those from PPA-
Rα +/+ mice. In addition, the beneficial effects of fenofi-
brate treatment on myocardial functions following
ischaemia reperfusion were lost and even worsened in
PPARα -/- mice leading us to conclude that this effect was
mediated through PPARα .
The hypothesis that nitric oxide (NO) may play a role in
the fenofibrate treatment-induced cardioprotection was
also tested by analyzing the expression of endothelial NO
synthase (eNOS) in hearts taken from either control or
fenofibrate treated mice. Western blot analysis showed
that fenofibrate treatment did not modify eNOS protein
expression in the heart (Fig. 4A). Likewise, fenofibrate
treatment did not affect the expression of the RNA of the
antioxidant genes Cu-Zn superoxide dismutase (Cu-Zn
SOD) or catalase (Fig. 4B,4C).
Fenofibrate enhances the participation of NO in modulat-
ing vasoconstriction
We next analyzed contractile responses in the aorta and in
the mesenteric vascular bed. In mesenteric vascular bed,
no significant differences in the changes in perfusion pres-
sure produced by the vasoconstrictor agonist, phenyle-
phrine were observed between control and fenofibrate-
treated mice (Table 2). Likewise, neurogenic vasoconstric-
tion of the mesenteric bed produced by electrical stimula-
tion was not different between the two groups of mice. In
the aorta, the thromboxane A2 analogue, U46619, pro-
duced a concentration-dependent contraction that was
not different between both groups of animals. This led us
to conclude that fenofibrate treatment did not modify the
contractile responses to vasoconstrictor agonists or to
Figure 4
Fenofibrate does not modified eNOS, catalase or Cu-Zn
SOD expresion in the heart. Representative Western-blot
(A) of eNOS protein expression in hearts from control mice
(CON) or mice treated with fenofibrate (FF). Positive con-
trol (C) is the eNOS from bovine endothelial cells. Similar
results were obtained in three separate experiments. Effect
of fenofibrate on catalase and Cu-Zn SOD mRNA expres-
sions in heart (B). Expression of catalase mRNA, Cu-Zn SOD
mRNA and the human acidic ribosomal phosphoprotein
36B4.
A C CON FF
- eNOS 130 kDa
B CON FF
- 28S
Catalase
18S-
- 28S
- 18S
Cu-Zn SOD
36B4
34 12 8 7 6 5BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/10
Page 5 of 10
(page number not for citation purposes)
electrical stimulation in the two vascular preparations
studies, mesenteric bed and the aorta (Table 2).
In the aorta, the NO-synthase inhibitor, L-NAME (300
µM) was without effect on U46619-induced contraction
in aorta rings from control mice (Fig. 5A), whereas it sig-
nificantly enhanced the sensitivity of the vasoconstrictor
agonist in aortas taken from fenofibrate-treated mice (Fig.
5B).
Fenofibrate improves endothelial function as a result of an 
increased anti-oxidant capacity of the vessel wall
The hypothesis that fenofibrate treatment improves en-
dothelial function was tested next by looking at the en-
dothelium-dependent relaxation to acetylcholine both in
the aorta and the mesenteric vascular bed. Interestingly,
both the mesenteric vascular bed (Fig. 6A) and the aorta
(Fig. 6B) from mice treated with fenofibrate displayed en-
hanced endothelium-dependent relaxation to acetylcho-
line, as compared to vascular preparations from control
mice.
The common endothelial factor released by the two vascu-
lar preparations is NO. Therefore, we investigated whether
the improvement of acetylcholine-induced relaxation in
vessels from fenofibrate treated animals could be ex-
plained by an enhanced participation of endothelial NO.
Western blot analysis showed that eNOS protein expres-
sion was not modified by the fenofibrate treatment both
in the mesenteric vascular bed and in the aorta (Fig.
6C,B,D), suggesting that the enhanced relaxation to ace-
tylcholine cannot be attributed to an increased expression
of eNOS protein in the two vascular preparations. Relaxa-
tion in response to the NO-donor, SNAP, was hence stud-
ied in both the mesenteric bed and the aorta, in order to
test the hypothesis of an increased response to NO or de-
creased of NO breakdown by reactive oxygen species. In
the two vascular preparations from fenofibrate-treated
mice, SNAP-mediated relaxation was significantly greater
than the relaxation obtained in vessels from control mice
(Fig. 7A,B). Interestingly, the combined addition of the
superoxide anion and the hydrogen peroxide scavengers,
SOD (200 U/ml) and catalase (750 U/ml) increased relax-
ation to SNAP in the aorta taken from control, but not in
that from fenofibrate-treated mice (Fig. 7C). The resulting
concentration-response curves to SNAP were hence not
significantly different in the aorta from the two groups of
mice in the presence of reactive oxygen scavengers. These
data suggest that the antioxidant capacity of aortic wall
from fenofibrate-treated mice was already sufficiently
high. In contrast to the situation in the controls, supple-
mentation with reactive oxygen scavengers (SOD and cat-
alase) could not further enhance the protection against
NO breakdown and the relaxation to SNAP. Increased
antioxidant capacity of the vessel wall from fenofibrate-
treated mice was not associated with an increased expres-
sion of mRNA for Cu-Zn SOD or catalase in the aorta and
mesenteric bed (data not shown).
Discussion
In the present study, we demonstrate that fenofibrate
treatment reduces the size of the myocardial infarction
and improves post-ischaemic contractile dysfunction.
This effect of fenofibrate is mediated via PPARα  activa-
tion. In addition we report that fenofibrate improves en-
dothelial NO-mediated vasodilatation both in the aorta
(conductance vessel) and in the mesenteric vascular bed
Table 2: Maximal effect (Emax) and EC50 values for phenyle-
phrine- and electrical stimulation induced increases in perfusion 
pressure in mesenteric bed and for U46619-induced contraction 
in aorta from control and fenofibrate-treated mice.
Control Fenofibrate
MESENTERIC BED
Phenylephrine
Emax (mmHg) 22.14 ± 7.03 21.73 ± 5.55
EC50 (M) 1.46 ± 0.5810-5 2.12 ± 0.55 10-5
(n = 9) (n = 9)
Electrical stimulation
Emax (mmHg) 14.17 ± 1.88 15.15 ± 2.06
(n = 7) (n = 9)
AORTA
U46619
Emax (mN/mm) 4.91 ± 0.34 5.16 ± 0.37
EC50 (M) 2.95 ± 0.85 10-8 2.8 ± 0.83 10-8
(n = 6) (n = 6)
Figure 5
Fenofibrate enhances the participation of NO in modulating
vasoconstriction. Concentration-effect curves for U46619-
induced vasoconstriction obtained in thoracic aorta rings of
control (A) and fenofibrate-treated (B) mice in the absence
or presence of Nw-nitro-L-arginine methyl ester (L-NAME,
300 µM). Data are the mean ± SEM of 6–7 experiments. *P <
0.05.
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(which contains small arteries that participate actively in
the regulation of peripheral resistance and thus blood
pressure). Increased anti-oxidant capacity of the vessel
wall, but not increased eNOS expression or increased sen-
sitivity to NO of the vascular smooth muscle accounts for
this enhancement of endothelial vasodilatation.
The function of PPARα  in the heart with respect to cardi-
oprotection against severe ischaemia has not yet been
documented. Here, we provide evidence that fenofibrate
treatment reduces the infarct size after ischaemia. Further-
more, fenofibrate treatment shortened the time of recov-
ery of the heart after an ischaemic insult and increased the
percentage of heart that recovered from ischaemia. More-
over, fenofibrate treatment markedly improved contrac-
tile function. It should be noted that fenofibrate treatment
did not produce any beneficial effect in heart from PPA-
Rα -/- mice. Finally, heart from PPARα -/- mice displayed in-
creased susceptibility to ischaemia/reperfusion-induced
functional injury versus those from PPARα +/+ mice. Alto-
gether these results show that fenofibrate through the ac-
tivation of PPARα  exerts a cardio-protective effect. The
Figure 6
Fenofibrate improves endothelial function. Acetylcholine-
induced relaxation in mesenteric bed (A) and thoracic aorta
(B). Results were expressed as a percent of the initial phe-
nylephrine- or U46619-induced pre-contraction level. The
values of contraction obtained with phenylephrine (10 µM) in
mesenteric bed from control and fenofibrate-treated mice
were 10.8 ± 1.1 mmHg (n = 9) and 11.44 ± 1.5 mmHg (n = 9),
respectively. The values of contraction obtained with
U46619 (30 nM) in aorta from control and fenofibrate-
treated mice were 3.26 ± 0.2 mN/mm (n = 8) and 3.01 ± 0.2
mN/mm (n = 8) respectively. Data are the mean ± SEM of 8–
9 experiments. * P < 0.05, ** P < 0.01. Representative West-
ern-blot of endothelial NO-synthase (eNOS) protein expres-
sion in mesenteric bed (C) and thoracic aortic segments (D)
from control (CON) and fenofibrate-treated (FF) mice. Posi-
tive control (C) is the eNOS from bovine endothelial cells.
Similar results were obtained in three separate experiments.
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Figure 7
Fenofibrate increases anti-oxidant capacity of the vessel wall.
Concentration-effect curves to the NO-donor S-N-
acetylpenicillamine (SNAP) obtained in mesenteric bed (A)
and thoracic aorta rings (B). Concentration-effect curves to
SNAP obtained in aorta rings in the presence (C) of superox-
ide dismutase (SOD, 200 U/ml) plus catalase (750 U/ml).
Results were expressed as a percent of the initial U46619-
induced precontraction level. The values of contraction
obtained with U46619 (0.3 µM for mesenteric bed and 30
nM for aorta) were 22.4 ± 5.6 mmHg (n = 5) and 28 ± 4.9
mmHg (n = 6) in mesenteric bed and 3.55 ± 0.15 mN/mm (n
= 7) and 3,37 ± 0.2 mN/mm (n = 6) in aorta from control and
fenofibrate-treated mice, respectively. Pretreatment with
SOD and catalase did not affect contractile responses to
U46619 (data not shown). Data are the mean ± SEM of 5–7
experiments. * P < 0.05, ** P < 0.01.
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mechanisms that may explain these effects of fenofibrate
are not fully understood. In the heart, PPARα  has been re-
ported to regulate cardiac lipid and energy metabolism,
by controlling genes encoding the mitochondrial fatty
acid  β -oxidation pathway, which provides the major
source of energy under the form of ATP to the heart mus-
cles [4]. The use of PPARα -/- mice has provided evidence
for the role of PPARα  in the control of cardiac lipid utili-
zation. Although PPARα -/- mice appear normal under ba-
sal conditions, the constitutive expression of protein and
enzymes involved in fatty acid transport and metabolism
are all significantly lower in heart and liver compared to
age matched control [10–14]. The reduction in fatty acid
transport and metabolism may hence explain the in-
creased accumulation of lipid, the decreased energy con-
sumption, and the reduction ATP content in hearts from
PPARα -/- mice. These above reports are supported by our
data showing that hearts from PPARα -/- mice were more
susceptible to ischaemic insults when compared to those
from PPARα +/+ animals. Indeed, the levels of post-ischae-
mic recovery of contractile force, heart rate and coronary
flow were lower in hearts from PPARα -/-versus PPARα +/+
mice. In mice in which PPARα  gene is valid, PPARα  ago-
nists such as fenofibrate would favour the maintenance of
adequate energy levels, to protect against the fall in ATP
during ischaemia by increasing the expression of genes in-
volved in fatty acid utilization, and therefore the content
of ATP. This may explain the improved survival of cardio-
myocytes and their resistance to ischaemia, as well as the
preservation of cardiac contractile function. Most of is-
chaemia-reperfusion injury is ultimately due to a burst of
reactive oxygen species that occurs upon readmission of
oxygen [15,16]. One of the potential mechanisms, which
contribute to protection against ischaemia-reperfusion
damage by fenofibrate, may be an increase in the antioxi-
dant capacity of the heart due to the induction of antioxi-
dant enzymes. Indeed, under certain conditions,
activation of PPARα  in vivo has been reported to cause an
induction of mRNA and protein levels of antioxidant en-
zymes, such as catalase, Cu-Zn SOD, and mediators of
glutathione pathway [5,17,18] which may be able to
counterbalance, at least partly, the deleterious effects of
oxidative stress during the reperfusion. In the present
study, no increased expression of Cu-Zn SOD or catalase
mRNA was observed within the heart. Finally, PPARα  ac-
tivation decreases inflammatory gene response by inhibit-
ing NFκ B and AP-1 activity, and by establishing a new
redox balance caused by oxidant stress-related disease
states [5,17,18]. The later would be responsible for the in-
crease in defence mechanisms towards the myocardial in-
farction and reduced myocardial effects of ischaemia.
PPARα  has also been identified in different vascular cell
types including endothelial, smooth muscle cells and
monocyte/macrophages [3,19]. There is growing evidence
that the effect of PPARα  activation may not solely be re-
stricted to an improvement in the atherogenic lipoprotein
profile, but may also be caused by a direct beneficial effect
on vessel wall [20]. The early stages of atherosclerosis may
result from an insult to the endothelium, a reduction in
the production of protective and relaxant factors (i.e. NO,
prostacyclin or endothelium-dependent hyperpolarizing
factor), or both factors combined. This may consequently
induce other changes, such as the expression of adhesion
molecules, the reduction of barrier function, and the up-
take of lipoproteins into the sub-endothelial matrix. Al-
though inhibition of NFκ B and AP-1 could limit the
secretion of endothelin-1 by endothelial cells or reduce
vascular cell adhesion molecule-1 expression, no direct
studies have looked at the beneficial effect of fenofibrate
treatment on endothelial function. In the present study,
we demonstrated that fenofibrate treatment improved
acetylcholine-induced relaxation in the aorta and in the
mesenteric vascular bed with regard to endothelium-de-
pendent vasodilatation. A reduced contractility of the ves-
sels to vasoconstrictor agonists cannot account for the
enhanced relaxation, because the levels of pre-contrac-
tions were matched between vascular beds from either
control or fenofibrate-treated mice. Furthermore, fenofi-
brate treatment did not affect the response elicited by
nerve stimulation nor that produced by the alpha1-adren-
oceptor agonist, phenylephrine at least in the mesenteric
bed. Interestingly, the use of the NO synthase inhibitor
unmasked the enhanced participation of NO in the regu-
lation of vasoconstrictor activity in the aorta from fenofi-
brate-treated mice. The most relevant hypothesis to
explain the enhanced relaxation to acetylcholine upon
fenofibrate treatment might be an increase in either gen-
eration (i.e. synthesis or release) of, or response to en-
dothelial relaxant factors. Alternatively, an alteration in
the balance between endothelial relaxing and constricting
factors can be invoked.
One of the major endothelial vasodilator factor and
which is also common to the two vascular preparations
studied (i.e., aorta and mesenteric bed) is NO, the reduced
participation of which has been implicated in diseases
linked to endothelial dysfunction [21]. Furthermore, NO
has been shown to inhibit platelet aggregation [22], to
limit the flux of the atherogenic plasma proteins into the
artery walls [23] and in the longer term, to induce the ex-
pression of genes protective to the cardiovascular system
[24]. Fenofibrate-induced increased participation of en-
dothelial NO cannot be attributed to an increased expres-
sion of the eNOS protein, both in aorta and mesenteric
bed, even though an increased enzymatic activity cannot
be fully ruled out. The increased relaxation to acetylcho-
line may, however, result from an increased sensitivity of
the smooth muscle cell to NO, as shown by the improve-
ment of the vasodilator effect of the NO donor, SNAP, inBMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/10
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vessels taken from fenofibrate-treated mice. It is interest-
ing to note that the superoxide anion scavengers, SOD
and catalase, were able to potentiate the effect of SNAP-in-
duced relaxation in the aorta from control mice, but not
in those from fenofibrate-treated mice. Thus, the vasodila-
tory response to the NO donor was not different in the
two groups after blockade of superoxide anion produc-
tion. This would imply that the antioxidant capacity of the
aortic wall from fenofibrate-treated mice was sufficiently
high, that the supplementation with reactive oxygen scav-
engers could not produce any further protection against
NO breakdown nor a further increase in relaxation to
SNAP. Therefore, the most and parsimonious hypothesis
to explain the enhanced endothelium-dependent relaxa-
tion to acetylcholine after fenofibrate treatment is an in-
creased antioxidant defence of the vessel wall, that
preserves endothelial NO from breakdown by the super-
oxide anions. Up-regulation of mediators of the glutath-
ione pathway [5,17,18] or down regulation of the
superoxide generating enzyme, NADPH oxidase [18]
might account for the effect fenofibrate since we did not
observe any changes in the expression of Cu-Zn SOD or
catalase in the aorta and the mesenteric bed.
In conclusion, the present study proves that treatment
with the PPARα  agonist, fenofibrate, has protective effects
against myocardial infarction induced by severe ischae-
mia and significantly improves endothelial vasodilata-
tion. All the above effects of PPARα  agonists open new
therapeutic perspectives for such compounds in ischaemic
myocardial injury and in cardiovascular diseases associat-
ed with endothelial dysfunction, secondary to pro-inflam-
matory or oxidant stress-related disease states.
Materials and methods
Animals and general issues
All animal experimentation was performed in accordance
with institutional guidelines, and protocols were ap-
proved by the French Animal Care Comittee in accord-
ance with European regulations.
This study was performed in male adult mice (C57BL/6
strain, 13–15 week-old). Mice were housed at 20°C with a
12 h light cycle, and allowed free access to food and water.
One group of animals (control) received placebo and the
second received during 10 days, fenofibrate mixed in the
food at 0.5 % w/w (15 mg/day) [2]. The dose used is in the
range of that commonly reported in mice in which no tox-
ic effect of fenofibrate has been observed as assessed by al-
teration in body weight at least in PPARα +/+ mice [2,25–
27]. To test whether the effect of fenofibrate was due to ac-
tivation of PPARα , a group of PPARα -/- mice (25%
C57BL/6, 75% SV-129) also received fenofibrate for 10
days. To further study the role of PPARα , on ischaemic in-
sult, comparisons were made between PPARα +/+versus
PPARα -/- mice (25% C57BL/6, 75% SV-129). Prior to ex-
perimentation, mice were anaesthetised with ketamine
(100 mg/kg i.p.), medetomidine (50 µg/kg i.p.) and
heparinized (500 U/kg i.p).
Isolated perfused heart
The heart was excised, cannulated and perfused according
to Langendorffat 37°C and pH 7.4 with Krebs-Henseleit
solution containing (mM) NaCl 118, NaHCO3 24, KCl 4,
MgCl2 1.2, NaH2PO4 1, CaCl2 2.5, Na2EDTA 0.5 and glu-
cose 10, gassed with 95%O2/5% CO2. Perfusion pressure
was constant and equivalent to 80 cm H2O. The heart was
stretched to a force of 1 g. The preparation was equilibrat-
ed for 30 min, then subjected to 30 min global no-flow is-
chaemia at 37°C.
Morphological analysis of cardiac ischaemic damage by triphenylene-
tetrazolium chloride (TTC)-staining
After the ischaemic insult followed by 1 h reperfusion,
hearts were stored at -20°C during 24 h. After this period,
the hearts were sliced transversally (2 mm thickness) and
incubated at 37°C with TTC for 15 min. Slices were then
fixed with 10% formalin for 20 min. After scanning the
slice, measurements of stained and unstained TTC areas of
the hearts were carried out by the use of a planimeter. The
infarct size was calculated as a percentage of the total ven-
tricular volume minus cavities.
Evaluation of cardiac function and post-ischaemic recovery
Mechanical activity of hearts from control and fenobi-
brate-treated mice were studied at baseline condition and
during 60 min reperfusion following 30 min ischaemia.
Cardiac parameters were monitored continuously and in-
cluded cardiac developed force (g), heart rate (beats/min)
and coronary flow (ml/min).
Vascular reactivity experiments
Mesenteric vascular perfused bed
The mesenteric bed was perfused via the main mesenteric
artery with physiological salt solution (PSS) with the fol-
lowing composition in mM: NaCl 119; KCl 4.7; KH2PO4
0.4; NaHCO3 15; MgSO4 1.17; CaCl2 2.5 and glucose 5.5,
and was mounted in a perfusion system. Flow rate was ad-
justed at 2 ml/min with PSS maintained at 37°C and con-
tinuously gassed with 95%O2/5%CO2 (pH 7.4). Agonists
were administered intraluminally. Changes in perfusion
pressure (∆ P, mmHg) were measured with a pressure
transducer and recorded by a physiograph. Concentra-
tion-response curves to the vasodilator agents acetylcho-
line or the NO donor, S-nitroso-N-acetylpenicillamine
(SNAP; Sigma, Grenoble, France) were performed on me-
senteric bed pre-contracted with either phenylephrine or
the thromboxane A2 analogue 9,11-dideoxy-9α ,11α -
methanoepoxy Prostaglandin F2α  (U46619; Cayman
Chemical Company, USA). Also, concentration-responseBMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/10
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curves to phenylephrine were constructed. Finally, the
mesenteric bed was subjected to nerve stimulation using a
tungsten bipolar electrode. Rectangular pulses (0.2 ms,
100 mA) were applied at 7 min intervals for 10 s at various
frequencies (5, 10, 15 and 20 Hz).
Aortic ring preparations
Segments of 2 mm of intact aorta were mounted on a wire
myograph [28] filled with PSS continuously kept at 37°C
and gassed with 95% O2/5%CO2 (pH 7.4) and mechani-
cal activity was recorded isometrically. Concentration-re-
sponse curves were constructed by cumulative application
of U46619 in the absence or in the presence of the NO-
synthase inhibitor, Nω  nitro-L-arginine methyl ester (L-
NAME, 300 µM). In another set of experiments, endothe-
lium-dependent relaxation to acetylcholine (0.01–100
µM) or endothelium-independent relaxation to the exog-
enous NO-donor, SNAP (0.01–100 µM) were examined
in vessels pre-contracted with U46619. Concentration-re-
sponse curves to SNAP were also constructed in the ab-
sence or in the presence of the superoxide anion and the
hydrogen peroxide scavengers, superoxide dismutase
(SOD, 200 U/ml) and catalase (750 U/ml). The inhibitors
were added into the bath 25 min prior to the pre-contrac-
tion with U46619.
Western blot analysis
Cytosolic proteins either from heart, mesenteric bed or
aorta were subjected to SDS-PAGE using 7% gels. After
electrophoresis, proteins were transferred to nitrocellu-
lose membranes and were probed with a monoclonal
mouse anti-endothelial NO-synthase (eNOS) antibody
(Transduction Laboratories, Montluçon, France). Bound
antibodies were detected with a secondary peroxidase-
conjugated anti-mouse antibody (Bio-Rad, Ivry sur Seine,
France). The bands were visualized using the enhanced
chemiluminescence system (ECL, Amersham, Bucking-
hamshire, UK) and quantified by densitometry.
RNA analysis
RNA preparation, northern blotting and quantification of
total cellular RNA derived from heart, aorta and mesenter-
ic bed were performed as described previously [2]. Blots of
heart tissues were hybridized with 32P-labeled cDNAs
corresponding to full length mouse Cu-Zn SOD (Gen-
Bank Accession Number X06683) and mouse catalase
(GenBank Accession Number L25069, nt 1109–1504).
The human acidic ribosomal phosphoprotein 36B4 probe
was used as a marker for equal loading [29]. Reverse tran-
scription of RNA was performed at 37°C for 1 h using M-
MLV reverse transcriptase (Life Technologies) and oligo
dT, followed by a 15 min inactivation at 70°C. Quantifi-
cation of aortic and mesenteric bed mRNA for Cu-Zn SOD
and catalase was carried out by real time PCR using a
LightCycler and the DNA double-stranded specific SYBR
Green I dye for detection (Roche, Basel, Switzerland).
Data analysis and statistics
All results are expressed as mean ± SEM of n experiments,
n representing the number of mice. The sensitivities to va-
soconstrictor agonists are expressed as EC50 values which
represent the half maximally effective molar concentra-
tion. Statistical evaluation was carried out using two-way
analysis of variance (ANOVA) or unpaired Student's t-test.
The level of significance was P < 0.05.
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